Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Progression of Hematopoietic Diseases in Shanghai, China

This study has been completed.
Sponsor:
Collaborators:
Fudan University
University of Cincinnati
ExxonMobil Biomedical Sciences, Inc.
British Petroleum-Amoco
Chevron
ConocoPhillips
Exxon Mobil
Marathon Ashland
Shell Chemicals
Information provided by (Responsible Party):
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT00365014
First received: August 14, 2006
Last updated: July 19, 2013
Last verified: July 2013

August 14, 2006
July 19, 2013
August 2003
December 2009   (final data collection date for primary outcome measure)
blood diseases presenting at Shanghai hospitals [ Time Frame: hospital stay ] [ Designated as safety issue: No ]
characterization of people with blood diseases presenting at Shanghai hospitals
Not Provided
Complete list of historical versions of study NCT00365014 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Progression of Hematopoietic Diseases in Shanghai, China
Analysis of Disease Progression for Aplastic Anemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia and Benzene Poisoning in Shanghai, China.

The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility.

The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility. The format for these studies is a set of clinical series superimposed on a case-control design that enables integration of detailed clinical and molecular characterizations of disease pathogenesis together with an evaluation of potential confounding and interacting factors within a structured statistical analysis of benzene exposure.

Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Patients with blood diseases

Hematologic Diseases
Not Provided
Blood disease patients
People with blood diseases presenting at Shanghai hospitals
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10757
December 2009
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

Men and women 18 years or older Diagnosis of hematologic abnormality

Exclusion Criteria:

Children Non hematologic diseases

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
China
 
NCT00365014
02-0036
Not Provided
University of Colorado, Denver
University of Colorado, Denver
  • Fudan University
  • University of Cincinnati
  • ExxonMobil Biomedical Sciences, Inc.
  • British Petroleum-Amoco
  • Chevron
  • ConocoPhillips
  • Exxon Mobil
  • Marathon Ashland
  • Shell Chemicals
Principal Investigator: Richard D Irons, PhD University of Colorado at Denver and Health Sciences Ctr.
University of Colorado, Denver
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP